Skip to content

One-year Efficacy of Adjunctive Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients with Glaucoma Inadequately Controlled under Maximum Medical Therapy

One-year Efficacy of Adjunctive Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients with Glaucoma Inadequately Controlled under Maximum Medical Therapy - One-year efficacy of Ripasudil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000026228
Enrollment
50
Registered
2017-02-20
Start date
2014-12-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prymary open angle glaucoma

Interventions

None listed

Sponsors

Department of Ophthalmology and Micro-technology, Yokohama City University School of Medicine, Yokohama, Japan
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Japanese men or women with primary open angle glaucoma,20 years of age or older, inadequately controlled IOP despite treatment with 3 or 4 drugs, IOP of less than 35 mmHg, and IOP difference less than 2 mm Hg between any 2 eligibility visits. We fixedthe target IOP at 18 mm Hg in the early phase, 15 mmHg in the intermidiate phase, and 12mm Hg in the late phase, according to Anderson's classification. We defined inadequately controlled IOP as a failure to decrease the IOP to its target value under the existing medical therapy.

Exclusion criteria

Exclusion criteria: The exclusion criteria were as follows: presence of secondary, steroid-related, or traumatic glaucoma, and narrow angles that are defined as grade 2 or less according to the Shaffer classification, as assessed using gonioscopy. We also excluded patients who had undergone ocular surgeries, including cataract surgery within the previous year; retinal laser treatment, selective laser trabeculoplasty, glaucoma surgery, or Nd:YAG laser posterior capsulotomy within the previous 90 days; and eyelid surgery within the previous 120 days. Patients with a corrected visual acuity worse than 20/200 in either eye or with severe visual field defects were also excluded.

Design outcomes

Primary

MeasureTime frame
Intraocular pressure lowering effect at 12 months after treatment

Countries

Japan

Contacts

Public ContactHiroshi Inazaki

Department of Ophthalmology and Micro-technology, Yokohama City University School of Medicine, Yokoh Ophthalmology

ojionobao@yahoo.co.jp045-261-5656

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026